Methods for detecting prostate cancer
First Claim
Patent Images
1. A method for detecting prostate cancer in a subject comprising measuring kallikrein 11 and prostate specific antigen (PSA) in a sample from the subject.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to the application of kallikrein 11, free PSA, and total PSA in the detection of prostate cancer. These markers may be used for the diagnosis, monitoring, staging, progression, prevention, treatment, and prognosis of prostate cancer, and as indicators before surgery or after relapse. A particular aspect of the invention provides a method for distinguishing prostate cancer from benign prostatic hyperplasia (BPH).
-
Citations
54 Claims
- 1. A method for detecting prostate cancer in a subject comprising measuring kallikrein 11 and prostate specific antigen (PSA) in a sample from the subject.
- 10. A method for distinguishing prostate cancer from benign prostatic hyperplasia (BPH) in a subject comprising determining the amount of kallikrein 11 contained in a sample from the subject, and relating the amount to the presence of prostate cancer or BPH in the subject.
-
27. A method for determining the presence of BPH or prostate cancer in a subject comprising:
-
(a) providing a first binding agent that specifically binds to kallikrein 11;
(b) providing a second binding agent that specifically binds to PSA;
(c) contacting the first agent and second agent with the sample under a condition that allows the formation of a first complex comprising the first agent and the kallikrein 11, and a second complex comprising the second agent and the PSA;
(d) determining the presence or amount of the first and second complexes;
(e) mathematically combining the amount of the first and second complexes; and
(f) relating the combination to the presence of BPH or prostate cancer. - View Dependent Claims (28, 29, 30)
-
-
39. (canceled)
-
40. A kit for determining the presence of BPH or prostate cancer in a subject, comprising:
-
(a) a known amount of a first binding agent that specifically binds to kallikrein 11; and
(b) a known amount of a second binding agent that specifically binds to PSA;
wherein the first and second binding agents comprise a detectable substance, or bind directly or indirectly to a detectable label.
-
-
41-49. -49. (canceled)
Specification